1 Top Wall Street Analyst Thinks CVS Health Could Jump Another 13%. Should You Load Up on the Stock?
Key Points
Earlier this month, Mizuho's Ann Hynes raised her price target to $115 per share.
Following the latest rally, this implies potential upside of around 13%.
Potential upside could be even greater for CVS Health shares, given the valuation of other healthcare service stocks, plus the prospect of further strong earnings growth.
- 10 stocks we like better than CVS Health ›
After a rough start to 2026, CVS Health (NYSE: CVS) shares have more than made up for their initial losses, surging in recent months on the heels of promising Medicare-related developments. Shares are already up over 25% year to date.
But even as shares keep climbing toward the top of sell-side analyst price targets, including the most recently raised price target, don't assume the runway is limited to this figure. Given CVS's strong comeback and potential rerating, it could remain one of the best-performing blue chip stocks this year.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Image source: Getty Images
The latest price target raise for CVS Health
On June 8, Mizuho analyst Ann Hynes, while reiterating her bullish rating on CVS Health, raised her price target by 4.5%, from $110 to $115 per share. With shares trading around $97 at the time, this represented about 18.5% upside, but CVS Health's subsequent rally has narrowed that to about 13%.
Following the stock's latest rally, investor sentiment has shifted strongly. Investors are likely no longer anticipating just "better than expected" results. There may now be an increasing pool of investors who believe that the company can continue to beat expectations. I believe this view is more than reasonable, with the potential for shares to reach levels above Mizuho's aforementioned target.
Loftier price levels within reach
Currently, CVS Health trades for just under 13.8 times forward earnings. If the stock were to rise to $115 per share, based on forecasts calling for 2026 earnings of $7.43 per share, CVS Health would be trading at a forward multiple of around 15.5.
The market now fully understands that CVS is a diversified healthcare services company today, similar to UnitedHealth Group. With UnitedHealth now rerated to a forward valuation in the low 20s, such a valuation may be reasonable for CVS as well, especially as forecasts call for further double-digit earnings growth in 2027. If this stock were to rise to a forward multiple in the high teens, or even up to 20 times forward earnings, it could hit prices near $150 per share.
Should you buy stock in CVS Health right now?
Before you buy stock in CVS Health, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and CVS Health wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $433,268!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,259,391!*
Now, it’s worth noting Stock Advisor’s total average return is 935% — a market-crushing outperformance compared to 207% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of June 15, 2026.
Thomas Niel has positions in UnitedHealth Group. The Motley Fool recommends CVS Health and UnitedHealth Group. The Motley Fool has a disclosure policy.
Recommended Articles
